Cancer screening

We are currently working on this topic, answering the following questions:

  1. How can cancer screening programmes targeting breast, cervical and colorectal cancers, be improved throughout the EU?
  2. What is the scientific basis for extending such screening programmes to other cancers e.g. lung, prostate and gastric cancers, and ensuring their feasibility
    throughout the EU?
  3. Which are the main scientific elements to consider, and best practices to promote, for optimising risk-based cancer screening and early diagnosis throughout the EU?

Why are we working on this topic?

The European Commission will make a proposal by 2022 to update the Council Recommendation on cancer screening to ensure it reflects the latest available scientific evidence. One of the objectives will be to consider the extension of cancer screening beyond breast, colorectal and cervical cancer to include prostate, lung and gastric cancer, and other cancers if supported by scientific evidence.

In advance of this proposal, the European Commission's Group of Chief Scientific Advisors will develop a Scientific Opinion on this topic.

For more information about SAPEA's work on this topic, please contact FEAM.


Working group members

Not yet available
Members of the working group will be listed here once the report is published
How do we find our experts?

Subscribe to our newsletter